Filtered By:
Specialty: Neurology
Condition: ALS
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 158 results found since Jan 2013.
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study (P3.155)
Conclusions: This long-term prospective observational study of a wide cohort of patients confirms that ultrasonographically guided BoNT-A injections represents an effective and safe treatment for sialorrhea in different neurologic disorders.Disclosure: Dr. Barbero has nothing to disclose. Dr. Artusi has nothing to disclose. Dr. De Mercanti has nothing to disclose. Dr. Tinivella has nothing to disclose. Dr. Busso has nothing to disclose. Dr. Clerico has nothing to disclose. Dr. Durelli has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Barbero, P., Artusi, C. A., De Mercanti, S., Tinivella, M., Busso, M., Clerico, M., Durelli, L. Tags: Neuromuscular Disease: Therapeutics Source Type: research
Amyotrophic Lateral Sclerosis (ALS) with Laboratory Abnormalities of Unknown Significance (LAUS) --Where Does It Begin and Where Does It End? (P4.144)
CONCLUSIONS: Further detailed analysis of progression rate by site of onset, sex, age, treatment will require assimilation of clinic-based datasets of properly analyzed ALS-LAUS patients from multiple clinic sites. The appropriate role of IVIg in ALS-LAUS patients requires further study following explication of the natural history of these patients compared with non-ALS-LAUS patients. The determination as to whether auto-antibodies to additional antigens may play a role in the progression rate of ALS-LAUS compared with sporadic ALS needs to be systematically studied. Study Supported by: Carolinas ALS Research FundDisclosur...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Langford, V., Alwan, M., Smith, N., Lucas, N., Nichols, M., Belcher, S., Lary, C., Nemeth, J., Russo, P., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Sanjak, M. Tags: Neuroepidemiology: ALS Source Type: research
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (I8-1B)
CONCLUSIONS: Interim evaluation of the primary objective-safety/tolerability and secondary objective-clinical endpoint responsiveness of MN-166 60 mg/day versus placebo administered for six months with riluzole in subjects with ALS will be presented for the first 30 patients. Study Supported by: Medicinova and Carolinas ALS Research FundDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Bravver has nothing to disclose. Dr. Sanjak has nothing to disc...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Sanjak, M., Langford, V., Lary, C., Alwan, M., Nemeth, J., Russo, P., Smith, N., Lucas, N., Nichols, M., Belcher, S., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Matsuda, Tags: Advances in ALS and Other Motor Neuron Diseases Data Blitz Presentations Source Type: research
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (S50.005)
CONCLUSIONS: Interim evaluation of the primary objective-safety/tolerability and secondary objective-clinical endpoint responsiveness of MN-166 60 mg/day versus placebo administered for six months with riluzole in subjects with ALS will be presented for the first 30 patients. Study Supported by: Medicinova and Carolinas ALS Research FundDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Bravver has nothing to disclose. Dr. Sanjak has nothing to disc...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Sanjak, M., Langford, V., Lary, C., Alwan, M., Nemeth, J., Russo, P., Smith, N., Lucas, N., Nichols, M., Belcher, S., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Matsuda, Tags: Treatment Trials in Neuromuscular Diseases Source Type: research
Brain-Computer Interface after Nervous System Injury
This article presents a state-of-the-art review of BCI technology used after nervous system injuries, specifically: amyotrophic lateral sclerosis, Parkinson’s disease, spinal cord injury, stroke, and disorders of consciousness. Also presented is transcending, innovative research involving new treatment of neurological disorders.
Source: The Neuroscientist - November 11, 2014 Category: Neurology Authors: Burns, A., Adeli, H., Buford, J. A. Tags: Reviews Source Type: research
Amyotrophic Lateral Sclerosis (ALS)
ALS, Amyotrophic Lateral Sclerosis or Lou Gehrig's disease information sheet compiled by the National Institute of Neurological Disorders and Stroke (NINDS).
Source: NINDS Disorders: National Institute of Neurological Disorders and Stroke - October 26, 2014 Category: Neurology Source Type: research
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial
This study is registered with ClinicalTrials.gov, number NCT00349622. Findings Stage 3 included 66 participants from stages 1 and 2 and 448 new participants. In total, 340 participants were randomly allocated to ceftriaxone and 173 to placebo. During stages 1 and 2, mean ALSFRS-R declined more slowly in participants who received 4 g ceftriaxone than in those on placebo (difference 0·51 units per month, 95% CI 0·02 to 1·00; p=0·0416), but in stage 3 functional decline between the treatment groups did not differ (0·09, −0·06 to 0·24; p=0·2370). No significant differences in survival between the groups were recorde...
Source: The Lancet Neurology - October 17, 2014 Category: Neurology Source Type: research
Transposed firing activation of motor units
Muscles are composed of groups of muscle fibers, called motor units, each innervated by a single motoneuron originating in the spinal cord. During constant or linearly varying voluntary force contractions, motor units are activated in a hierarchical order, with the earlier-recruited motor units having greater firing rates than the later-recruited ones. We found that this normal pattern of firing activation can be altered during oscillatory contractions where the force oscillates at frequencies ≥2 Hz. During these high-frequency oscillations, the activation of the lower-threshold motor units effectively decreases and tha...
Source: Journal of Neurophysiology - August 15, 2014 Category: Neurology Authors: De Luca, C. J., Kline, J. C., Contessa, P. Tags: Control Of Movement Source Type: research
Nogo-A: Multiple Roles in CNS Development, Maintenance, and Disease
Initially discovered as a potent neurite outgrowth inhibitor in the central nervous system (CNS), Nogo-A has emerged as a multifunctional protein. Involvement of this protein has been demonstrated in numerous developmental processes, ranging from cell migration, axon guidance and fasciculation, dendritic branching and CNS plasticity to oligodendrocyte differentiation and myelination. Although initially necessary and beneficial for shaping and later maintaining CNS structure and functionality, the growth restricting properties of Nogo-A can have negative effects on nervous system injury or disease. Hence, correlating with i...
Source: The Neuroscientist - July 15, 2014 Category: Neurology Authors: Schmandke, A., Schmandke, A., Schwab, M. E. Tags: Reviews Source Type: research
Emerging Subspecialties in Neurology: Neuropalliative care
Palliative medicine, as defined by World Health Organization, is the specialty that recognizes and attempts to prevent or alleviate physical, social, psychological, and spiritual suffering.1 Understanding the principles of palliative care should be an essential component of neurologic training, as the trajectory of many neurologic illnesses is progressive and incurable.2 Given the delicate nature of many of the conversations that neurologists have with patients at the time of diagnosis or during acute illness and hospitalization, expertise in discussing a patient's wishes, handling difficult conversations, and providing ad...
Source: Neurology - May 26, 2014 Category: Neurology Authors: Robinson, M. T., Barrett, K. M. Tags: Palliation pain, Palliative care RESIDENT AND FELLOW SECTION Source Type: research
Vitamin D Is A Prognostic Factor Of Amyotrophic Lateral Sclerosis And Confers Protection To Motoneurons In Vitro (P4.084)
CONCLUSIONS:Our findings suggest that vitamin D as a reliable prognostic factor of ALS and support a neuroprotective function of vitamin D on MNs in vitro.Study Supported by:Disclosure: Dr. William has received personal compensation for activities with Novartis, Merck & Co. Inc., Sanofi-Aventis Pharmaceuticals Inc., Biogen Idec, and Actelion. Dr. Tremblier has nothing to disclose. Dr. Plassot has nothing to disclose. Dr. Alphandery has nothing to disclose. Dr. Salsac has nothing to disclose. Dr. Pageot has nothing to disclose. Dr. Juntas-Morales has nothing to disclose. Dr. Scamps has nothing to disclose. Dr. Daures ha...
Source: Neurology - April 9, 2014 Category: Neurology Authors: William, C., Tremblier, B., Plassot, C., Alphandery, S., Salsac, C., Pageot, N., Juntas-Morales, R., Scamps, F., Daures, J. P., Raoul, C. Tags: ALS: Trials and Biomarkers Source Type: research
Serum Creatinine, a Biomarker for Muscle Mass in Amyotrophic Lateral Sclerosis (ALS), Predicts Loss of Ambulation Measured by ALS Functional Rating Scale-Revised Walking Item Score (ALSFRS-Rw) (P4.085)
CONCLUSIONS:Decrease in serum creatinine significantly predicted change in ambulation measured by ALSFRS-Rw longitudinally.Further analysis is required to determine whether leg function alone and leg muscle mass are the major determinants of serum creatinine in ALS patients over the course of the disease.Study Supported by:Carolinas ALS Research Fund/Pinstripes Fund/Carolinas Garden of Hope/Carolinas Healthcare FoundationDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Dis...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Brooks, B., Fischer, M., Sanjak, M., Holsten, S., Kandinov, B., Bockenek, W., Bravver, E., Desai, U., Story, J. S., Pacicco, T., Lindblom, S., Langford, V., Wright, K., Ward, A., Lucas, N., Smith, N., Nichols, M., Lary, C., Nemeth, J., Russo, P. Tags: ALS: Trials and Biomarkers Source Type: research
Use of Veterans Specific Activity Questionnaire VSAQ to Estimate Exercise Tolerance in Ambulatory Amyotrophic Lateral Sclerosis (ambALS) Patients (P2.071)
CONCLUSIONS:VSAQ is a practical tool to estimate exercise capacity of ambALS and may be used for safe exercise prescription.Disclosure: Dr. Sanjak has nothing to disclose. Dr. Headen has nothing to disclose. Dr. Barrett has nothing to disclose. Dr. Holsten has nothing to disclose. Dr. Langford has nothing to disclose. Dr. Bravver has received research support from Biogen Idec, Avanier, Cytokinetics Pharmaceuticals, Neuraltus Pharmaceuticals, GlaxoSmithKline Inc., the National Institute of Neurological Disorders and Stroke, and the Clinical Research Consortium. Dr. Bockenek has nothing to disclose. Dr. Desai has received pe...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Sanjak, M., Headen, J., Barrett, K., Holsten, S., Langford, V., Bravver, E., Bockenek, W., Desai, U., Story, J. S., Lindblom, S. C., Paccico, T., Brooks, B. Tags: ALS: Genetics and Outcomes Source Type: research
Relationship Between Bone Mass And Muscle Weakness In Chronic Neurological Diseases (P3.036)
Conclusions: This study demonstrates greater commitment tendency to bone density in regions with weakness, compared to those without it, this could be related to disuse. This series had insufficient vitamin D. The neurologist should consider bone mass evaluation in patients with chronic muscle weakness.Disclosure: Dr. Gutierrez has nothing to disclose. Dr. Rodriguez has nothing to disclose. Dr. Garcea has nothing to disclose. Dr. Rey has nothing to disclose. Dr. Lepera has nothing to disclose. Dr. Monica has nothing to disclose. Dr. Monica has nothing to disclose. Dr. Eduardo has nothing to disclose. Dr. Berenice has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Gutierrez, M., Rodriguez, G. E., Garcea, D., Rey, R., Lepera, S., Monica, E., Monica, D., Eduardo, K., Berenice, S. Tags: General Neurology II Source Type: research
Walking Capacity WalkCap Measured by Six-Minute Walk (6MW) Does Not Demonstrate Fatigue in Patients with Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS),and Parkinson Disease (PD) (P3.071)
CONCLUSIONS:WalkCap of ambulatory ALS, MS, and PD during 6MW is not affected by motor fatigue. WalkCap was higher in ambulatory patients with stronger grip, faster in TUG and 25FW. WalkCap measured by 6MW can be used as a simple outcome measure to evaluate lower extremity impairments in various neurological diseases. Discordance between WalkCap and the UPDRS-motor scale in mildly affected PD patients indicates that 6MW may provide additional information regarding these patients in clinical practice and clinical research trials.Study Supported by:Carolinas ALS Research Fund, Pinstripes Fund, Carolinas Healthcare Foundation,...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Sanjak, M., Morgan, L., Simpson, A., Holsten, S., Hirsch, M., Englert, D., Iyer, S., Conway, J., Kaufman, M., Bravver, E., Desai, U., Russo, P., Brooks, B. Tags: Movement Disorders: Assessing Parkinson ' s Disease Source Type: research
